

## Publikationen 2006

### Originalarbeiten

Ananworanich J, Gayet-Ageron A, Le Braz M, Prasithsirikul W, Chetchotisakd P, Kiertiburanakul S, Munsakul W, Raksakulkarn P, Tansuphasawasdikul S, Sirivichayakul S, Cavassini M, Karrer U, Genne D, Nuesch R, Vernazza P, Bernasconi E, Leduc D, Satchell C, Yerly S, Perrin L, Hill A, Perneger T, Phanuphak P, Furrer H, Cooper D, Ruxrungtham K, Hirschel B. CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial. *Lancet* 2006;368(9534):459-65.

Audige A, Urosevic M, Schlaepfer E, Walker R, Powell D, Hallenberger S, Joller H, Simon HU, Dummer R, Speck RF. Anti-HIV state but not apoptosis depends on IFN signature in CD4+ T cells. *J Immunol* 2006;177(9):6227-37.

Baenziger S, Tussiwand R, Schlaepfer E, Mazzucchelli L, Heikenwalder M, Kurrer MO, Behnke S, Frey J, Oxenius A, Joller H, Aguzzi A, Manz MG, Speck RF. Disseminated and sustained HIV infection in CD34+ cord blood cell-transplanted Rag2-/-gamma c-/- mice. *Proc Natl Acad Sci U S A* 2006;103(43):15951-6.

Bertschy S, Opravil M, Cavassini M, Bernasconi E, Schiffer V, Schmid P, Flepp M, Chave JP, Christen A, Furrer H. Discontinuation of maintenance therapy against toxoplasma encephalitis in AIDS patients with sustained response to anti-retroviral therapy. *Clin Microbiol Infect* 2006;12(7):666-71.

Buehlmann M, Chave JP, Flepp M, Schiffer V, Keiser O, Furrer H. Tenofovir-containing nucleoside/nucleotide-only antiretroviral maintenance therapy: decision making and virological outcome. *HIV Clin Trials* 2006;7(2):48-54.

Franceschi S, Polesel J, Rickenbach M, Dal Maso L, Probst-Hensch NM, Fux C, Cavassini M, Hasse B, Kofler A, Ledergerber B, Erb P, Clifford GM. Hepatitis C virus and non-Hodgkin's lymphoma: Findings from the Swiss HIV Cohort Study. *Br J Cancer* 2006;95(11):1598-602.

Funk GA, Oxenius A, Fischer M, Opravil M, Joos B, Flepp M, Weber R, Gunthard HF, Bonhoeffer S. HIV replication elicits little cytopathic effects in vivo: analysis of surrogate markers for virus production, cytotoxic T cell response and infected cell death. *J Med Virol* 2006;78(9):1141-6.

Gaudieri S, Rauch A, Park LP, Freitas E, Herrmann S, Jeffrey G, Cheng W, Pfafferott K, Naidoo K, Chapman R, Battegay M, Weber R, Telenti A, Furrer H, James I, Lucas M, Mallal SA. Evidence of viral adaptation to HLA class I-restricted immune pressure in chronic hepatitis C virus infection. *J Virol* 2006;80(22):11094-104.

Glass TR, De Geest S, Weber R, Vernazza PL, Rickenbach M, Furrer H, Bernasconi E, Cavassini M, Hirschel B, Battegay M, Bucher HC. Correlates of self-reported nonadherence to antiretroviral therapy in HIV-infected patients: the Swiss HIV Cohort Study. *J Acquir Immune Defic Syndr* 2006;41(3):385-92.

Glass TR, Ungsedhapand C, Wolbers M, Weber R, Vernazza PL, Rickenbach M, Furrer H, Bernasconi E, Cavassini M, Hirschel B, Battegay M, Bucher HC.

Prevalence of risk factors for cardiovascular disease in HIV-infected patients over time: the Swiss HIV Cohort Study. *HIV Med* 2006;7(6):404-10.

Huber M, Fischer M, Misselwitz B, Manrique A, Kuster H, Niederost B, Weber R, von Wyl V, Gunthard HF, Trkola A. Complement lysis activity in autologous plasma is associated with lower viral loads during the acute phase of HIV-1 infection. *PLoS Med* 2006;3(11):e441:2078-2093.

Hurlimann D, Chenevard R, Ruschitzka F, Flepp M, Enseleit F, Bechir M, Kobza R, Muntwyler J, Ledergerber B, Luscher TF, Noll G, Weber R. Effects of statins on endothelial function and lipid profile in HIV infected persons receiving protease inhibitor-containing antiretroviral combination therapy: a randomised double blind crossover trial. *Heart* 2006;92(1):110-2.

Joos B, Trkola A, Kuster H, Aceto L, Fischer M, Stiegler G, Armbruster C, Vcelar B, Katinger H, Gunthard HF. Long-term multiple-dose pharmacokinetics of human monoclonal antibodies (MAbs) against human immunodeficiency virus type 1 envelope gp120 (MAb 2G12) and gp41 (MAbs 4E10 and 2F5). *Antimicrob Agents Chemother* 2006;50(5):1773-9.

Kaiser P, Niederost B, Joos B, von Wyl V, Opravil M, Weber R, Gunthard HF, Fischer M. Equal amounts of intracellular and virion-enclosed hepatitis C virus RNA are associated with peripheral-blood mononuclear cells in vivo. *J Infect Dis* 2006;194(12):1713-23.

Keiser O, Martinez de Tejada B, Wunder D, Chapuis-Taillard C, Zellweger C, Zinkernagel AS, Elzi L, Schmid P, Bernasconi E, Aebi-Popp K, Rickenbach M. Frequency of gynecologic follow-up and cervical cancer screening in the Swiss HIV cohort study. *J Acquir Immune Defic Syndr* 2006;43(5):550-5.

Knuchel MC, Tomasik Z, Speck RF, Luthy R, Schupbach J. Ultrasensitive quantitative HIV-1 p24 antigen assay adapted to dried plasma spots to improve treatment monitoring in lowresource settings. *J Clin Virol* 2006;36(1):64-7.

Lapaire O, Irion O, Koch-Holch A, Holzgreve W, Rudin C, Hoesli I. Increased peri- and postelective cesarean section morbidity in women infected with human immunodeficiency virus-1: a case-controlled multicenter study. *Arch Gynecol Obstet* 2006;274(3):165-169.

Law MG, Friis-Moller N, El-Sadr WM, Weber R, Reiss P, D'Arminio Monforte A, Thiebaut R, Morfeldt L, De Wit S, Pradier C, Calvo G, Kirk O, Sabin CA, Phillips AN, Lundgren JD. The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D Study. *HIV Med* 2006;7(4):218-30.

Mocroft A, Phillips AN, Ledergerber B, Katlama C, Chiesi A, Goebel FD, Knysz B, Antunes F, Reiss P, Lundgren JD. Relationship between antiretrovirals used as part of a cART regimen and CD4 cell count increases in patients with suppressed viremia. *Aids* 2006;20(8):1141-50.

Muller NJ, Furrer H, Kaiser L, Hirschel B, Cavassini M, Fellay J, Chave JP, Wuthrich RP, Weber M, Mullhaupt B, Candinas D, Reichen J, Giostra E, Mentha G, Halkic N,

Hirsch HH, Weber R. HIV and solid organ transplantation: the Swiss experience. *Swiss Med Wkly* 2006;136(11-12):194-6.

Muller V, Ledergerber B, Perrin L, Klimkait T, Furrer H, Telenti A, Bernasconi E, Vernazza P, Gunthard HF, Bonhoeffer S. Stable virulence levels in the HIV epidemic of Switzerland over two decades. *Aids* 2006;20(6):889-94.

Pillai SK, Pond SL, Liu Y, Good BM, Strain MC, Ellis RJ, Letendre S, Smith DM, Gunthard HF, Grant I, Marcotte TD, McCutchan JA, Richman DD, Wong JK. Genetic attributes of cerebrospinal fluid-derived HIV-1 env. *Brain* 2006;129(Pt 7):1872-83.

Podlekareva D, Mocroft A, Dragsted UB, Ledergerber B, Beniowski M, Lazzarin A, Weber J, Clumeck N, Vetter N, Phillips A, Lundgren JD. Factors associated with the development of opportunistic infections in HIV-1-infected adults with high CD4+ cell counts: a EuroSIDA study. *J Infect Dis* 2006;194(5):633-41.

Puoti M, Cozzi-Lepri A, Arici C, Moller NF, Lundgren JD, Ledergerber B, Rickenbach M, Suarez-Lozano I, Garrido M, Dabis F, Winrock M, Milazzo L, Gervais A, Raffi F, Gill J, Rockstroh J, Ourishi N, Mussini C, Castagna A, De Luca A, Monforte A. Impact of lamivudine on the risk of liver-related death in 2,041 HBsAg- and HIV-positive individuals: results from an inter-cohort analysis. *Antivir Ther* 2006;11(5):567-74.

Rabodonirina M, Nahimana A, Weber R, Francioli P, Bille J, Hauser PM. Geographical Variation in the Prevalence of Pneumocystis jirovecii Dihydropteroate Synthase Mutations Within Western Europe. *J Eukaryot Microbiol* 2006;53 Suppl 1:S112-3.

Schlaepfer E, Audige A, Joller H, Speck RF. TLR7/8 triggering exerts opposing effects in acute versus latent HIV infection. *J Immunol* 2006;176(5):2888-95.

Schubach J, Tomasik Z, Knuchel M, Opravil M, Gunthard HF, Nadal D, Boni J. Optimized virus disruption improves detection of HIV-1 p24 in particles and uncovers a p24 reactivity in patients with undetectable HIV-1 RNA under long-term HAART. *J Med Virol* 2006;78(8):1003-10.

Simcock M, Sendi P, Ledergerber B, Keller T, Schubach J, Battegay M, Gunthard HF. A longitudinal analysis of healthcare costs after treatment optimization following genotypic antiretroviral resistance testing: does resistance testing pay off? *Antivir Ther* 2006;11(3):305-14.

The Antiretroviral Therapy Cohort Collaboration (Ledergerber B, member of the analysis and writing committee): Rates of disease progression according to initial highly active antiretroviral therapy regimen: A collaborative analysis of 12 prospective cohort studies. *Journal of Infectious Diseases* 194:612-622, 2006.

Vora S, Marcelin AG, Gunthard HF, Flandre P, Hirsch HH, Masquelier B, Zinkernagel A, Peytavin G, Calvez V, Perrin L, Yerly S. Clinical validation of atazanavir/ritonavir genotypic resistance score in protease inhibitor-experienced patients. *Aids* 2006;20(1):35-40.

Weber R, Sabin CA, Friis-Moller N, Reiss P, El-Sadr WM, Kirk O, Dabis F, Law MG, Pradier C, De Wit S, Akerlund B, Calvo G, Monforte A, Rickenbach M, Ledergerber

B, Phillips AN, Lundgren JD. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. *Arch Intern Med* 2006;166(15):1632-41.

Widmer IC, Erb P, Grob H, Itin P, Baumann M, Stalder A, Weber R, Cathomas G. Human herpesvirus 8 oral shedding in HIV-infected men with and without Kaposi sarcoma. *J Acquir Immune Defic Syndr* 2006;42(4):420-5.

Zinkernagel AS, von Wyl V, Ledergerber B, Rickenbach M, Furrer H, Battegay M, Hirschel B, Tarr PE, Opravil M, Bernasconi E, Schmid P, Weber R. Eligibility for and outcome of hepatitis C treatment of HIV-coinfected individuals in clinical practice: the Swiss HIV cohort study. *Antivir Ther* 2006;11(2):131-42.

## **Kollaborationen**

INITIO trial International co-ordinating committee: DA Cooper (joint chair NCHECR), P Yeni (joint chair Groupe Hospitalier Bichat). J-P Aboulker (INSERM SC10), F Antunes (national principal investigator, Portugal), A Babiker (MRC CTU), M Becker (Roche), N Boukli (INSERM SC10), F Brun-Vezinet (joint chair Virology group), D Carey (NCHECR), D Churchill (joint national principal investigator, UK), B Conway (national principal investigator, Canada), C Chazallon (INSERM SC10), J Darbyshire (MRC CTU), S De Wit (national principal investigator, Belgium), B Dusak (Dupont), S Emery (NCHECR), M Flepp (national principal investigator, Switzerland), M Florida (ISS), J Gatell (national principal investigator, Spain), P-M Girard (national principal investigator, France), R L Goodall (MRC CTU), R Hemmer (national principal investigator, Luxembourg), M Hooker (MRC CTU), M Law (NCHECR), C Loveday (joint chair Virology Group) J Lundgren (national principal investigator, Denmark), D Manion (Dupont), V Meiff redy (INSERM SC10), A Mijch (national principal investigator, Australia and New Zealand), F Mulcahy (National Principal Investigator, Ireland), A Orani (national principal investigator, Italy), C Pharo (GSK), M Ristola (national principal investigator, Finland), B Salzberger (joint national principal investigator, Germany), E Sandstrom (national principal investigator, Sweden), M Schechter (national principal investigator, Brazil), S Schnittman (Bristol Myers Squibb), M Seligmann (chair immunology group), S Staszewski (joint national principal investigator, Germany), M Stek (Merck), W Verbiest (VIRCO), J Weber (joint national principal investigator, UK), R Withnall (Secretary). Virological and immunological outcomes at 3 years after starting antiretroviral therapy with regimens containing non-nucleoside reverse transcriptase inhibitor, protease inhibitor, or both in INITIO: open-label randomised trial. *Lancet* 2006; 368:287-98.

The SMART Study Group (Mueller N. is a member of the Study Group). Strategies for Management of Antiretroviral Therapy (SMART) Study Group: CD4+ count-guided interruption of antiretroviral treatment. *N Engl J Med* 2006;355: 2283-96.

The Antiretroviral Therapy Cohort Collaboration (B. Ledergerber is a steering committee member of the ART Cohort Collaboration). HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis. *Lancet* 368:451-458, 2006

## **Uebersichtsartikel / Reviews**

Bertisch B, Rued C. [Pneumocystis jiroveci pneumonia (PcP) in patients with rheumatic diseases: case report and review]. *Z Rheumatol* 2006;65(1):18-20, 22-3.

Bischoff H, Mueller NJ. Vitamin D, Licht und Tuberkulose: Wenn die Alten plötzlich Recht bekommen. *Chemother J* 2006;15:172-4.

Fluckiger U, Marchetti O, Bille J, Eggimann P, Zimmerli S, Imhof A, Garbino J, Rued C, Pittet D, Tauber M, Glauser M, Calandra T. Treatment options of invasive fungal infections in adults. *Swiss Med Wkly* 2006;136(29-30):447-63.

Gaemperli A, Hauser T, Speck R. [Risk of infection during treatment with tumor necrosis factor-alpha inhibitors]. *Z Rheumatol* 2006;65(1):24-8, 30-1.

Huttner B, Opravil M. [Infectious spondylitis]. *Z Rheumatol* 2006;65(1):7-11.

Laffer R, Rued C. [Diagnosis and treatment of prosthetic joint infections]. *Z Rheumatol* 2006;65(1):12, 14-7.

Mueller NJ, Fishman JA. How should we evaluate organ donors with active or prior infections? *J Hepatol* 2006;45(4):507-13.

Mueller NJ, Fishman JA. Infectious risk in xenotransplantation. *Curr Opin Organ Transplant* 2006;11:180-4.

Seebach JD, Mueller NJ. Xenotransplantation: Bald klinische Realität? *Schweiz Med Forum* 2006;6:374-5.

Sudano I, Spieker LE, Noll G, Corti R, Weber R, Luscher TF. Cardiovascular disease in HIV infection. *Am Heart J* 2006;151(6):1147-55.

## **Editorials**

Rued C. Antibiotic Treatment of Diseases Without an Evident Infectious Etiology. *Infection* 2006;34(6):299.

Rued C. Five years after 9/11-fearing smallpox. and the vaccine against it. *Infection* 2006;34(5):239-40.

Rued C. MRSA decolonization--is it feasible? *Infection* 2006;34(3):117.

Rued C. What's the Best Way to Measure Antibiotic Use in Hospitals? *Infection* 2006;34(2):53-54.

Rued C. New forms of antibiotic delivery for the treatment of foreign body infections. *Infection* 2006;34(1):1.

## **Buchkapitel**

Fischer M. Spuren des HI-Virus unter antiretroviraler Therapie. Chronos Verlag Zürich, 2006, Hg, Kurt Schäfer und Karin Stüber.

Rued C. Infektionsprävention in der Chirurgie, 47 pp. ComMed Verlagsagentur: Basel (2006)

## **Andere Arbeiten**

Colombo C. Vogelgrippe: Damit die „Spanische Grippe“ nicht zurückkehrt. Krankenpflege 2006;6:10-14.

Weber R. Abklärung und Therapie der Lyme-Borreliose bei Erwachsenen und Kindern. Replik zu Letter to the Editor. Schweiz. Ärztezeitung 2006;87:298-299.

### **Dissertationen**

Kaiser Philipp. Dissertation an der Medizinischen Fakultät der Universität Zürich. Even Distribution of Virion-bound and Intracellular Hepatitis C Virus RNA in Peripheral Blood Mononuclear Cells.

### **Diplomarbeiten:**

Corthésy S. Diplomarbeit an der ETH Zürich. Identification and Characterization of Novel HIV Entry Inhibitors: High Throughput Screening and Generation of CD4-specific Designed Ankyrin Repeat Proteins.

### **Originalpublikationen in print (2007) bis 31.01.2007**

Agnellini P, Wolint P, Rehr M, Cahenzli J, Karrer U, Oxenius A. Impaired NFAT nuclear translocation results in split exhaustion of virus-specific CD8+ T cell functions during chronic viral infection PNAS, in press

Allers K, Knoepfle LS, Rauch P, Walter H, Opravil M, Fischer M, Günthard HF, Metzner KJ. Persistence of Lamivudine-Sensitive HIV-1 Quasispecies in the Presence of Lamivudine In Vitro and In Vivo. J Acquir Immune Defic Syndr 2007.

Bochud PY, Hersberger M, Taffé P, Bochud M, Stein CM, Calandra T, Francioli P, Telenti A, Speck RF, Aderem A and the #SHCS. Polymorphisms in Toll-like Receptors Gene Influence Susceptibility to HIV Infection and its Clinical Course. AIDS 2007;21:441-446.

Bremi P, Günthard HF, Forster A. Belastungsabhängige Leistenschmerzen links bei chronischer HIV-1 Infektion. Schweizerische Rundschau für Medizin (Praxis) 2007; (in press).

Elzi L, Schlegel M, Weber R, Hirschel B, Cavassini M, Schmid P, Bernasconi E, Rickenbach M, Furrer H. Reducing tuberculosis incidence by tuberculin skin testing, preventive treatment, and antiretroviral therapy in an area of low tuberculosis transmission. Clin Infect Dis 2007;44(1):94-102.

Fenner L, Weber R, Steffen R, Schlagenhauf P (2007) Spectrum of travel associated infectious disease in relation to purpose of travel". Emerging Infectious Diseases (accepted).

Knuchel MC, Jullu B, Shah C, Tomasik Z, Stoeckle MP, Speck RF, Nadal D, Mshinda H, Boni J, Tanner M, Schupbach J. Adaptation of the Ultrasensitive HIV-1 p24 Antigen. J Acquir Immune Defic Syndr 2007;44:247-253

Ladell K, Dorner M, Zauner L, Berger C, Zucol F, Niggli F, Speck RF, Nadal D. Immune activation suppresses initiation of lytic Epstein-Barr Virus infection. Accepted in Cellular Microbiology.

Mocroft, Staszewski S, Weber R, Gatell J, Rockstroh J, Gasiorowski J, Panos G, d'Arminio Monforte A, Rakhmanova A, Phillips AN, Lundgren JD, on behalf of the EuroSIDA study group\* (2007) Risk of discontinuation of nevirapine due to toxicities in antiretroviral naive and experienced HIV-infected patients with high and low CD4 counts. *Antiviral Therapy* (in press)

Rampini SK, Lüthi B, Rued C, Speck RF. Clostridium difficile assoziierter Durchfall: "an emerging infection". *Der Gastroenterologe* 2007. In press

Rauch A, Laird R, McKinnon E, Telenti A, Furrer HJ, Weber R, Smillie D, Gaudieri S; and the Swiss HIV Cohort (200x). Influence of inhibitory KIRs and their HLA-C ligands on resolving HCV infection. *Study Tissue Antigens* (in press).

Rotger M, Tegude H, Colombo S, Cavassini M, Furrer H, Decosterd L, Blievernicht J, Saussele T, Gunthard HF, Schwab M, Eichelbaum M, Telenti A, Zanger UM. Predictive Value of Known and Novel Alleles of CYP2B6 for Efavirenz Plasma Concentrations in HIVinfected Individuals. *Clin Pharmacol Ther* 2007.

Sendi P, Gunthard HF, Simcock M, Ledergerber B, Schupbach J, Battegay M. Cost-Effectiveness of Genotypic Antiretroviral Resistance Testing in HIV-Infected Patients with Treatment Failure. *PLoS ONE* 2007;2:e173.

Thiel MA, Zinkernagel AS, Burhenne J, Kaufmann C, Haefeli WE. Voriconazole concentration in human aqueous humor and plasma during topical or combined topical and systemic administration for fungal keratitis. *Antimicrob Agents Chemother* 2007;51(1):239-44.

Wunder DM, Bersinger NA, Fux CA, Mueller NJ, Hirschel B, Cavassini M, Elzi L, Schmid P, Bernasconi E, Mueller B, Furrer HJ, and the Swiss HIV Cohort Study. Hypogonadism in HIV-1 infected men is frequent and does not resolve during antiretroviral therapy. *Antivir Ther.* 2007, in press.

Zimbwa P, Milicic A, Frater J, Scriba TJ, Willis A, Goulder PJ, Pillay T, Gunthard H, Weber JN, Zhang HT, Phillips RE. Precise identification of a human immunodeficiency virus type 1 antigen processing mutant. *J Virol* 2007;81(4):2031-2038.

### **Uebersichtsartikel / Reviews in print (2007) bis 31.01.2007**

Huber M, Trkola A. Humoral Immunity to HIV-1: Neutralization and Beyond. *Journal of Internal Medicine.* 2007. In press.

Huber M, Olson WC, Trkola A. Antibodies for HIV treatment and prevention: Window of opportunity? *Current Topics in Microbiology and Immunology.* 2007. In press.

### **Buchkapitel in print (2007) bis 31.01.2007**

Infektionen beim alten Menschen. U. Karrer und K.H. Krause, *Klinische Infektiologie*, 2. Auflage, Elsevier GmbH, Urban & Fischer Verlag, 2007

Weber R, Mathis A, Deplazes P. Microsporidia, p.xxxx-xxxx. In: Murray PR, Baron EJ, Jorgensen JH, Pfaller MA, Tenover FC, Tenover FC (eds.) *Manual of Clinical Microbiology.*

American Society for Microbiology, 9th Edition, ASM Press, Washington D.C. 2007  
(in press).